产品
编 号：F740780
分子式：C11H12ClFN2
分子量：226.68
分子式：C11H12ClFN2
分子量：226.68
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 169675-08-5
产品详情
生物活性：
Ro60-0175 is a potent and selective agonist of 5-HT2C receptor. Ro60-0175 reduces self-administration.
体内研究：
Ro60-0175（1 mg/kg；皮下注射）保留了在药物治疗组的对照动物中观察到的规律性反应，但药物治疗的动物更早达到它们的转折点。Ro60-0175（0.3、1 和 3 mg/kg；皮下注射）显着降低恢复组对主动杠杆的响应。Ro60-0175（0.5mg/kg SB242084；1mg/kg Ro60-0175；皮下注射）与恢复组中的载体相比降低了反应，并且通过 SB242084 预处理可以防止这种效应。对于对非活动杠杆的响应，没有显着的主效应或交互作用。Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:1 mg/kg
Administration:s.c.
Result:Preserved the regularity of responding seen in control animals in drug-treated group, but drug-treated animals reached their break-points earlier.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.5?mg/kg (SB242084), 1?mg/kg (Ro60-0175)
Administration:s.c. (Ro60-0175), i.p. (SB242084)
Result:Reduced responding for cocaine and effect was reversed by SB242084.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.3, 1, and?3 mg/kg (Ro60-0175), 1?mg/kg (yohimbine)
Administration:s.c. (Ro60-0175), i.p. (yohimbine)
Result:Showed yohimbine treatment alone increased responding relative to vehicle injection, and the response was attenuated dose dependently by Ro60-0175.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.5 mg/kg (SB242084), 1?mg/kg (Ro60-0175), 1?mg/kg (yohimbine)
Administration:s.c. (Ro60-0175), i.p. (yohimbine), i.p. (SB242084)
Result:Ro60-0175 reduced responding and that this effect was prevented by SB242084 pretreatment.
Ro60-0175 is a potent and selective agonist of 5-HT2C receptor. Ro60-0175 reduces self-administration.
体内研究：
Ro60-0175（1 mg/kg；皮下注射）保留了在药物治疗组的对照动物中观察到的规律性反应，但药物治疗的动物更早达到它们的转折点。Ro60-0175（0.3、1 和 3 mg/kg；皮下注射）显着降低恢复组对主动杠杆的响应。Ro60-0175（0.5mg/kg SB242084；1mg/kg Ro60-0175；皮下注射）与恢复组中的载体相比降低了反应，并且通过 SB242084 预处理可以防止这种效应。对于对非活动杠杆的响应，没有显着的主效应或交互作用。Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:1 mg/kg
Administration:s.c.
Result:Preserved the regularity of responding seen in control animals in drug-treated group, but drug-treated animals reached their break-points earlier.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.5?mg/kg (SB242084), 1?mg/kg (Ro60-0175)
Administration:s.c. (Ro60-0175), i.p. (SB242084)
Result:Reduced responding for cocaine and effect was reversed by SB242084.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.3, 1, and?3 mg/kg (Ro60-0175), 1?mg/kg (yohimbine)
Administration:s.c. (Ro60-0175), i.p. (yohimbine)
Result:Showed yohimbine treatment alone increased responding relative to vehicle injection, and the response was attenuated dose dependently by Ro60-0175.
Animal Model:Adult male Sprague-Dawley rats (280-320 g)
Dosage:0.5 mg/kg (SB242084), 1?mg/kg (Ro60-0175), 1?mg/kg (yohimbine)
Administration:s.c. (Ro60-0175), i.p. (yohimbine), i.p. (SB242084)
Result:Ro60-0175 reduced responding and that this effect was prevented by SB242084 pretreatment.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备